SCHEMBL7973340

SCHEMBL7973340

CCc1ccc(C(=O)NS(C)(=O)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.61
SCN9A Q15858 3/20 0.56
ALDH1A1 P00352 5/20 0.53
TDP1 Q9NUW8 1/20 0.53
NPC1 O15118 2/20 0.52
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
GAA P10253 4/20 0.50
P4HTM Q9NXG6 2/20 0.49
PTPN1 P18031 1/20 0.48
LMNA P02545 2/20 0.47
POLB P06746 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
AGTR1 P30556 1/20 0.47
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364340 0.87 RXRA (0.62) SCN9AALDH1A1TDP1NPC1POLB
SCHEMBL7987067 0.85 PLK1 (0.61) PLK1ALDH1A1TDP1NPC1TAS1R3
SCHEMBL10202053 0.84 SCN9A (0.50) PLK1SCN9AP4HTMPTPN1POLB
SCHEMBL13141179 0.84 HDAC6 (0.65) SCN9AP4HTMPTPN1POLBSMN1; SMN2
Diethylamine SCHEMBL16239678 0.82 RXRA (0.57) SCN9AALDH1A1TDP1NPC1SMN1; SMN2
SCHEMBL16747271 0.81 PLK1 (0.56) PLK1SCN9AALDH1A1TDP1NPC1
SCHEMBL7973254 0.81 PLK1 (0.56) PLK1ALDH1A1TDP1NPC1TAS1R3
SCHEMBL8442436 0.81 SCN9A (0.48) PLK1SCN9AP4HTMPTPN1POLB
SCHEMBL8337823 0.81 THRA (0.50) SCN9AP4HTMPTPN1POLBKDM4E
SCHEMBL6918025 0.80 PLK1 (0.70) PLK1ALDH1A1TDP1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714240-B2 Vinyl autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2017-07-25 US disclosed
US-7981881-B2 Fused heterocyclic compounds and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2011-07-19 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20080293650-A1 Fused Heterocyclic Compounds and Use Thereof BRISTOL-MYERS SQUIBB COMPANY 2008-11-27 US disclosed
US-7384937-B2 Fused heterocyclic compounds and use thereof BRISTOL-MYERS SQUIBB CO. (US) 2008-06-10 US disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
US-6331628-B1 REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 PLK1 2336/4885SCN9A 1341/4885ALDH1A1 1062/4885
US-20080293650-A1 Fused Heterocyclic Compounds and Use Thereof MCL1, FPR1, LTB4R PLK1 2877/4885SCN9A 3021/4885ALDH1A1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.